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NEW RESEARCH PAPERS
FOCUS ON CHRONIC TOTAL OCCLUSIONS
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ABSTRACT
BACKGROUND Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with increased risk
of periprocedural complications. Estimating the risk of complications facilitates risk-beneﬁt assessment and procedural
planning.
OBJECTIVES This study sought to develop risk scores for in-hospital major adverse cardiovascular events (MACE),
mortality, pericardiocentesis, and acute myocardial infarction (MI) in patients undergoing CTO PCI.
METHODS The study analyzed the PROGRESS-CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention; NCT02061436) and created risk scores for MACE, mortality, pericardiocentesis, and acute MI. Logistic
regression prediction modeling was used to identify independently associated variables, and models were internally
validated with bootstrapping.
RESULTS The incidence of periprocedural complications among 10,480 CTO PCIs was as follows: MACE 215 (2.05%),
mortality 47 (0.45%), pericardiocentesis 83 (1.08%), and acute MI 66 (0.63%). The ﬁnal model for MACE included $65
years of age (1 point), moderate-severe calciﬁcation (1 point), blunt stump (1 point), antegrade dissection and re-entry
(ADR) (1 point), female (2 points), and retrograde (2 points); the ﬁnal model for mortality included $65 years of age
(1 point), left ventricular ejection fraction #45% (1 point), moderate-severe calciﬁcation (1 point), ADR (1 point), and
retrograde (1 point); the ﬁnal model for pericardiocentesis included $65 years of age (1 point), female (1 point),
moderate-severe calciﬁcation (1 point), ADR (1 point), and retrograde (2 points); the ﬁnal model for acute MI included
prior coronary artery bypass graft surgery (1 point), atrial ﬁbrillation (1 point), and blunt stump (1 point). The C-statistics
of the models were 0.74, 0.80, 0.78, 0.72 for MACE, mortality, pericardiocentesis, and acute MI, respectively.
CONCLUSIONS The PROGRESS-CTO complication risk scores can facilitate estimation of the periprocedural complication risk in patients undergoing CTO PCI. (J Am Coll Cardiol Intv 2022;15:1413–1422) © 2022 by the American College
of Cardiology Foundation.
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C

ABBREVIATIONS
AND ACRONYMS
ADR = antegrade dissection
and re-entry

hronic total occlusion (CTO) percu-

stenosis and ﬁnal TIMI ﬂow grade 3. Major adverse

taneous

intervention

cardiovascular events (MACE) were deﬁned as the

(PCI) is associated with an increased

composite of death, MI, stroke, urgent repeat revas-

risk of complications.1,2 Assessment of the

cularization (re-PCI or surgery), or pericardiocentesis.

coronary

procedural risks and beneﬁts is essential for

Procedural success was deﬁned as technical success

operating characteristic curve

patient counseling and procedural planning.

in the absence of in-hospital MACE. MI was deﬁned

AW = antegrade wiring

While several scores have been developed

using the Third Universal Deﬁnition of Myocardial

to assess the likelihood of technical success

Infarction (type 4a MI). 12

AUC = area under the receiver-

CABG = coronary artery bypass
grafting

in CTO PCI,3-6 there are only a few tools

Calciﬁcation was assessed by angiography and

CTO = chronic total occlusion

that assess the risk of complications.7,8 We

classiﬁed as mild (spots), moderate and severe,

LVEF = left ventricular ejection

analyzed a large multicenter CTO PCI registry

deﬁned as #50% and $50% calciﬁcation compared

fraction

to

with reference lesion diameter, respectively.

MACE = major adverse

PROGRESS-CTO complications score,7 and to

For risk calculation purposes, antegrade wiring

cardiovascular event(s)

develop separate risk scores for in-hospital

(AW) was deﬁned as the absence of use of either

PCI = percutaneous coronary

mortality,

antegrade dissection and re-entry (ADR) or retrograde

intervention

update

the

previously

developed

pericardiocentesis,

and

acute

crossing attempts. If AW and ADR were both used, the

myocardial infarction (MI).

ROC = receiver-operating

case was classiﬁed as ADR. If a retrograde strategy was

SEE PAGE 1423

characteristic

used, the crossing strategy was deﬁned as retrograde.

METHODS

The study was approved by the Institutional Re-

The PROGRESS-CTO (Prospective Global Registry for

view Board of each site.

the Study of Chronic Total Occlusion Intervention;

STATISTICAL ANALYSIS. Continuous variables were

NCT02061436) includes CTO PCI procedures per-

presented as mean  SD and compared using the in-

formed at 40 centers from the United States, Canada,

dependent t test or Mann-Whitney U test, as appro-

Greece, Turkey, Egypt, Russia, and Lebanon between

priate.

2012 and 2022. The Research Electronic Data Capture

absolute numbers and percentages and compared

database

using the chi-square or Fisher exact test, as appro-

was

used

for

data

collection

and

Categorical

variables

were

presented

as

management. 9,10

priate. Univariable logistic regression was performed

DEFINITIONS. CTOs were deﬁned as the absence of

to identify associations between variables and out-

antegrade ﬂow through the lesion with a presumed or

comes (MACE, mortality, pericardiocentesis, acute

documented duration of $3 months with Thrombol-

MI). Variables that had a P value of <0.10 in the

ysis In Myocardial Infarction (TIMI) ﬂow grade 0 ac-

univariable analysis and considered clinically or an-

cording to the deﬁnition of the CTO Academic

giographically plausible predictors of MACE, mortal-

Research Consortium.11

ity, pericardiocentesis, or acute MI were tested in the

Technical success was deﬁned as the successful

multivariable logistic regression with a backward

recanalization of the CTO vessel with <30% residual

elimination approach starting with variables that
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had the highest P value separately in each model. All
dropped variables that were considered clinically or

T A B L E 1 Clinical, Angiographic, and Procedural Characteristics of Patients With and

Without In-Hospital Major Adverse Cardiovascular Events

angiographically plausible were then individually
added

to

investigate

any

other

potential

con-

founders by checking the change in the beta co-

Characteristics/Variables

Major In-Hospital
Adverse Cardiovascular
Events (n ¼ 215)

No Major In-Hospital
Adverse Cardiovascular
Events (n ¼ 10,272)

P Value

68  11 (192)

64  10 (9,191)

<0.001

efﬁcients in the multivariable regression model. The

Age, y

Hosmer-Lemeshow test was used to test goodness-

Male

142 (73.00)

7,628 (81.00)

0.004

of-ﬁt, with P > 0.05 considered a good ﬁt. The

LVEF, %

49  15 (170)

50  13 (8,097)

0.0789

discriminative capacity of the model was illustrated

BMI, kg/m2

30  6 (173)

30  6 (8,584)

0.250

with

Technical (angiographic) success

142 (66.00)

8,906 (87.00)

<0.001

the

receiver-operating

characteristic

(ROC)

curve, with an area under the ROC curve (AUC) 0.70

J-CTO score

2.9  1.1 (203)

2.4  1.3 (9,661)

<0.001

to 0.80 and 0.80 to 0.90 considered to have an

PROGRESS-CTO score

1.4  1.0 (150)

1.3  1.0 (7,911)

0.067

acceptable and excellent discrimination, respec-

Hypertension

177 (93.00)

8,227 (89.00)

0.152

tively.

Diabetes mellitus

71 (38.00)

3,894 (43.00)

0.149

2,341 (26.00)

Internal

validation

was

performed

with

bootstrapping 1,000 samples from the dataset. A

Smoking

0.026

calculator incorporating the variables in the ﬁnal

Current/recent (within 1 y)

34 (19.00)

prediction

Past (>1 y ago)

83 (46.00)

3,321 (37.00)

Never

65 (36.00)

3,244 (36.00)

1.3  1.1 (170)

1.2  0.9 (8,374)

0.127

24 (19.00)

808 (12.00)

0.027

Prior heart failure

73 (40.00)

2,540 (29.00)

0.001

Prior myocardial infarction

86 (48.00)

3,925 (45.00)

0.459

Prior percutaneous coronary
intervention

131 (64.00)

5,812 (62.00)

0.603

model

was

created

(Supplemental

Appendix) by calculating the probability of event
(P) with the logistic regression equation: ln(P/
(1P))¼ b0 þ b1 $x 1 þ . þ bz $x z. To ease clinical use

and for risk score assignment, age and left ventricular ejection fraction (LVEF) were transformed into
categorical variables and binary risk scores were
provided. Risk scores were created from the full
prediction model by assigning weighted points to
the beta coefﬁcients in the ﬁnal models.
Statistical analyses were performed using Stata
v17.0 (StataCorp).

Baseline creatinine, mg/dL
Atrial ﬁbrillation

Prior coronary artery bypass grafting

65 (31.00)

2,750 (29.00)

0.512

170 (89.00)

7,952 (87.00)

0.324

RHC during CTO PCI

23 (21.00)

214 (3.50)

<0.001

LV assist device used

44 (25.00)

315 (3.70)

<0.001

Cerebrovascular disease

25 (13.00)

907 (10.00)

0.146

Chronic lung disease

37 (20.00)

1,288 (14.00)

0.032

Dyslipidemia

On dialysis at baseline

RESULTS

Length of hospital stay, d

6 (3.20)

218 (2.40)

0.507

4 (2-7) (140)

1 (1-1) (7,616)

<0.001

2 (0.96)

47 (0.48)
2,556 (26.00)

CTO target vessel

0.793

BASELINE CHARACTERISTICS AND PROCEDURAL

Left main artery

OUTCOMES. Among 10,487 CTO PCIs, in-hospital

LAD

53 (25.00)

LCX

46 (22.00)

1,881 (19.00)

RCA

104 (50.00)

5,138 (53.00)

MACE occurred in 215 (2.05%), mortality in 47
(0.45%), pericardiocentesis in 83 (1.08%), and acute
MI in 66 (0.63%) (Supplemental Figure 1). Patients

SVG
Other

0 (0)

12 (0.10)

3 (1.40)

150 (1.50)

who experienced MACE were older (age 68  11 years

CTO lesion length >20 mm

131 (77.00)

5,733 (66.00)

0.005

vs 64  10 years; P < 0.001), more likely to be women

Moderate or severe calciﬁcation
(CTO lesion)

138 (67.00)

4,318 (46.00)

<0.001

(27% vs 19%; P ¼ 0.004), and to have a history of heart
failure (40% vs 29%; P ¼ 0.001), a history of chronic
lung disease (20% vs 14%; P ¼ 0.032), moderatesevere calciﬁcation (67% vs 46%; P < 0.001), higher

Orbital atherectomy
Rotational atherectomy
IVUS/OCT

3 (1.40)

86 (0.80)

0.377

20 (9.30)

338 (3.30)

<0.001

90 (55.00)

3,935 (47.00)

J-CTO score (2.9  1.1 vs 2.4  1.3; P < 0.001), and

AW

56 (26.00)

“lower” successful crossing with antegrade wiring

ADR

30 (14.00)

1,327 (13.00)

(26% vs 55%; P < 0.001). Technical success was

Retrograde

74 (34.00)

1,902 (19.00)

signiﬁcantly higher in patients without MACE (87% vs

None

55 (26.00)

1,298 (13.00)

66%; P < 0.001) (Table 1).
RISK

PREDICTION

cardiovascular

MODELS. M a j o r

e v e n t s . On

univariable

adverse
logistic

regression, age, female sex, atrial ﬁbrillation, LVEF,
proximal

cap

ambiguity,

0.059
<0.001

Successful crossing strategy
5,600 (55.00)

Values are mean  SD (n), n (%), or median (IQR) (n). ADR ¼ antegrade dissection and re-entry; AW ¼ antegrade
wiring; BMI ¼ body mass index; CTO ¼ chronic total occlusion; IVUS ¼ intravascular ultrasound; J-CTO ¼ JapanCTO; LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery; LV ¼ left ventricular; LVEF ¼ left
ventricular ejection fraction; OCT ¼ optical coherence tomography; PCI ¼ percutaneous coronary intervention;
PROGRESS-CTO ¼ Prospective Global Registry for the Study of Chronic Total Occlusion Intervention; RCA ¼ right
coronary artery; RHC ¼ right heart catheterization; SVG ¼ saphenous vein graft.

moderate-severe

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on August 22, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

1416

Simsek et al

JACC: CARDIOVASCULAR INTERVENTIONS VOL. 15, NO. 14, 2022
JULY 25, 2022:1413–1422

Risk Scores for Periprocedural Complications in CTO PCI

(Supplemental Appendix). The PROGRESS-CTO MACE

F I G U R E 1 PROGRESS-CTO Complication Risk Scores

score showed acceptable performance on the ROC
curve (AUC: 0.74; 95% CI: 0.70-0.78) (Figure 2A). The
Hosmer-Lemeshow

test

indicated

good

ﬁtness

(P ¼ 0.231), and internal validation with bootstrapping of 1,000 samples demonstrated a good
agreement with the model (observed AUC: 0.72; 95%
bias-corrected CI: 0.68-0.76).
We

validated

the

“old”

PROGRESS-CTO

complications score in the current dataset and
compared it with the updated PROGRESS-CTO MACE
score.

The

AUC

for

the

old

PROGRESS-CTO

complications score in the current dataset was 0.67
(95% CI: 0.63-0.70), and the updated MACE score had
better performance compared with the old score
(AUC: 0.74 vs 0.67; P ¼ 0.0002). At 2% MACE cutoff,
compared with the old score, in the updated MACE
score, 38 (27%) of 141 were reclassiﬁed higher and 6
(4%) of 141 were reclassiﬁed lower in the event group.
In the nonevent group, 938 (14%) of 6,860 were
reclassiﬁed higher and 394 (6%) of 6,860 were
reclassiﬁed lower (net reclassiﬁcation improvement:
0.15; 95% CI: 0.13-0.16; P ¼ 0.0018).
Age was dichotomized (<65 years and $65 years)
and risk points were assigned to each variable based
on the magnitude of OR (þ1 for >65 years of
age, þ2 for female sex, þ1 for moderate-severe
calciﬁcation, þ1 for blunt stump, þ1 for ADR, þ2 for
retrograde) (Figure 1A).
For each PROGRESS-CTO MACE risk score, the
corresponding MACE percentage risk and the proportion of patients falling in that category in the
PROGRESS-CTO registry were calculated (Figures 3A
to 3B, Central Illustration). The calculated risk percentages for MACE based on the PROGRESS-CTO
MACE score ranged from 0.43% to 11.73% for MACE;

Multiple logistic regression analyses and attributed risk scores for the PROGRESS-CTO
(Prospective Global Registry for the Study of Chronic Total Occlusion Intervention)

42% of patients had PROGRESS-CTO MACE score of 2

(A) major adverse cardiovascular events (MACE), (B) mortality, (C) pericardiocentesis, and

to 3, corresponding to a MACE risk of 1.10% to 2.60%.

(D) acute myocardial infarction (MI) risk scores. ADR ¼ antegrade dissection and re-

M o r t a l i t y . On univariable logistic regression, age,

entry; CABG ¼ coronary artery bypass grafting; LVEF ¼ left ventricular ejection frac-

LVEF, prior coronary artery bypass grafting (CABG)

tion; mod-sev. ¼ moderate-severe.

surgery, moderate-severe calciﬁcation, ADR, and
retrograde strategy were associated with a peri-

calciﬁcation, moderate-severe proximal vessel tortuosity, ADR, retrograde strategy, and blunt stump were
associated with MACE with a P value <0.10.

procedural death, with a P value <0.10.
The ﬁnal model included: 1) age (continuous); 2)
LVEF (continuous); 3) moderate-severe calciﬁcation

A multivariable logistic regression model to predict

(yes/no); and 4) crossing strategy (AW-ADR-retro-

MACE was built with these variables, and the ﬁnal

grade) (Figure 1B). The PROGRESS-CTO mortality risk

model was created as described in the Methods. The

calculator for clinical use was created with these

ﬁnal

2)

variables (Supplemental Appendix). The PROGRESS-

sex (male/female); 3) moderate-severe calciﬁcation

CTO mortality risk score showed an excellent per-

(yes/no); 4) crossing strategy (AW/ADR/retrograde);

formance with an AUC of 0.80 (95% CI: 0.73-0.86)

and

(Figure 2B). The Hosmer-Lemeshow test indicated

model

5)

included:

stump

1)

age

(blunt/tapered)

(continuous);

(Figure

1A).

The

PROGRESS-CTO in-hospital MACE risk calculator for

good ﬁt (P ¼ 0.85), and internal validation with

clinical

bootstrapping of 1,000 samples demonstrated a good

use

was

created

with

these

variables
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F I G U R E 2 Area Under the ROC Curve for the Complication Risk Scores

Area under the receiver-operating characteristic (ROC) curve for the (A) MACE, (B) mortality, (C) pericardiocentesis, and (D) acute MI risk
models. Abbreviations as in Figure 1.

agreement with the model (observed e: 0.71; 95%

the need for pericardiocentesis, with a P value <0.10.

bias-corrected CI: 0.63-0.81).

The ﬁnal model included: 1) age (continuous);

Age (<65 years and $65 years) and LVEF (#45%

2) sex (male/female); 3) moderate-severe calciﬁcation

and >45%) were dichotomized and risk points were

(yes/no);

assigned to each variable based on the magnitude of

retrograde) (Figure 1C). The PROGRESS-CTO peri-

OR (þ1 for >65 years of age, þ1 for LVEF #45%, þ1 for

cardiocentesis risk calculator for clinical use was

moderate-severe calciﬁcation, þ1 for ADR, and þ1 for

created

retrograde) (Figure 1B).

Appendix). The PROGRESS-CTO pericardiocentesis

and

with

4)

crossing

these

strategy

variables

(AW-ADR-

(Supplemental

For each PROGRESS-CTO mortality risk score, the

risk score had acceptable performance with an AUC

corresponding mortality percentage risk and the pro-

of 0.78 (95% CI: 0.72-0.83) (Figure 2C). The Hosmer-

portion of patients falling in that category in the

Lemeshow test indicated good ﬁtness (P ¼ 0.10),

PROGRESS-CTO registry were calculated (Figures 3C to

and internal validation with bootstrapping of 1,000

3D). The calculated risk percentages for mortality

samples demonstrated a good agreement with the

based on the PROGRESS-CTO mortality score ranged

model (observed AUC: 0.78; 95% bias-corrected CI:

from 0.05% to 2.42% for mortality, and 63% of patients

0.72-0.83).

had PROGRESS-CTO mortality score of 1 or 2, corresponding to a mortality risk of 0.10% to 0.50%.

Age (<65 years and $65 years) was dichotomized
and risk points were assigned to each variable based

P e r i c a r d i o c e n t e s i s . Patients with prior CABG were

on the magnitude of OR (þ1 for >65 years of age, þ1

excluded from the pericardiocentesis risk prediction

for

model, and the ﬁnal model was based on 7,672 CTO

calciﬁcation, þ1 for ADR, and þ2 for retrograde)

PCI cases and 83 (1.10%) perforations.

(Figure 1C).

female

sex,

þ1

for

moderate-severe

On univariable logistic regression, age, female

For each PROGRESS-CTO pericardiocentesis risk

sex, blunt stump, moderate-severe calciﬁcation, ADR,

score, the corresponding pericardiocentesis per-

and the retrograde approach were associated with

centage risk and the proportion of patients falling in
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F I G U R E 3 PROGRESS-CTO Complication Risk Scores and Corresponding Risk Percentages

The PROGRESS-CTO complication risk scores and corresponding risk percentage and percentage of patients in the respective risk group within the PROGRESS-CTO
registry for (A, B) MACE, (C, D) mortality, (E, F) pericardiocentesis, and (G, H) acute MI. The boxplots represent the risk percentage interval for a given PROGRESS-CTO
complication score (from top to bottom: maximum, quartile 3, median, quartile 1, minimum). The risk for a given complication score is not a single number but an
interval based on the variables the ﬁnal score is summed—variables with different beta coefﬁcients might be given the same score (eg, score of 1 each, rather than 1
and 1.3) for ease of use; however, this does not correspond to exactly the same risk. Abbreviations as in Figure 1.

that category in the PROGRESS-CTO registry were

For each PROGRESS-CTO acute MI risk score, the

calculated (Figures 3E to 3F). The calculated risk

corresponding acute MI percentage risk and the

percentages for pericardiocentesis based on the

proportion of patients falling in that category in

PROGRESS-CTO mortality score ranged from 0.18%

the

to 8.74% for pericardiocentesis, and 55% of patients

(Figures 3G to 3H). The calculated risk percentages for

had PROGRESS-CTO pericardiocentesis score of 1 or

acute MI based on the PROGRESS-CTO acute MI risk

2, corresponding to a pericardiocentesis risk of

score ranged from 0.18% to 2.83% for acute MI,

0.40% to 1.60%.

and 87% of patients had PROGRESS-CTO acute MI

A c u t e M I . On univariable logistic regression anal-

risk score of 0 or 1, corresponding to an acute MI risk

ysis; age, atrial ﬁbrillation, LVEF, diabetes mellitus,

of 0.18% to 0.50%.

PROGRESS-CTO

registry

were

calculated

prior PCI, prior CABG, proximal cap ambiguity,
stump,

moderate-severe

calciﬁcation,

and

CTO

DISCUSSION

length were associated with a periprocedural MI,
with a P value <0.10.

Our study identiﬁed risk factors for MACE, mortality,

The ﬁnal model included: 1) prior CABG; 2) atrial

pericardiocentesis, and acute MI in patients under-

ﬁbrillation; 3) prior MI; 4) stump; and 5) diabetes

going CTO PCI, and created 4 internally validated risk

mellitus (Figure 1D). The PROGRESS-CTO acute MI risk

scores and accompanying risk percentages with

calculator for clinical use was created with these var-

acceptable to excellent discrimination.

iables (Supplemental Appendix). The PROGRESS-CTO

Several scores have been developed to date to pre-

acute MI risk score showed acceptable performance,

dict technical success rates (the CL-SCORE [Clinical

as shown by the AUC (0.72; 95% CI: 0.62-0.82)

and Lesion-related]), 5 successful guidewire crossing

(Figure 2D). The Hosmer-Lemeshow test indicated

of a CTO lesion within 30 minutes (J-CTO [Japan-CTO]

good ﬁt (P ¼ 0.51), and internal validation with boot-

score),4 and technical success or failure (ORA [Ostial

strapping of 1,000 samples demonstrated good

location, Rentrop grade <2, Age $75 years], E-CTO

agreement with the model (bias-corrected AUC: 0.72;

[operator Experience CTO], Ellis; RECHARGE [Registry

95% CI: 0.65-0.80).

of CrossBoss and Hybrid procedures in FrAnce, the

Risk points were assigned to each variable based on

NetheRlands, BelGium and UnitEd Kingdom]; W-CTO

the magnitude of OR (þ1 for prior CABG, þ1 for atrial

[Weighted CTO], PROGRESS-CTO, and CASTLE-CTO

ﬁbrillation, þ1 for blunt stump) (Figure 1D).

[CABG, Age, Stump anatomy, Tortuosity degree,
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C ENTR AL I LL U STRA T I O N The PROGRESS-CTO In-Hospital MACE Risk Score

Age ≥65 years
+1 point

P

80
60
Age ≥65 years

GRESS CT
RO
O

Moderate-tosevere
calcification
+1 point
Blunt stump
+1 point

10,487 CTO PCIs performed at
40 centers in 7 countries
between 2012-2022
In-hospital MACE 2.05%

Female
+2 points

Technical success 86.3%
AUC: 0.74
Antegrade
dissection and
re-entry
+1 point
or
Retrograde
+2 points
Simsek B, et al. J Am Coll Cardiol Intv. 2022;15(14):1413–1422.

PROGRESS-CTO in-hospital MACE risk score. AUC ¼ area under the receiver-operating characteristic curve; CTO ¼ chronic total occlusion; MACE ¼ major adverse cardiovascular event(s); PCI ¼ percutaneous coronary intervention; PROGRESS-CTO ¼ Prospective Global Registry for the Study of Chronic Total Occlusion Intervention.

Length of occlusion, Extent of calciﬁcation-CTO]

The most recent American College of Cardiology/

scores) scores.3,6,13-17 However, only 2 scores, the

American Heart Association/Society for Coronary

PROGRESS-CTO complications score 7 and the coro-

Angiography and Interventions guidelines for coro-

nary perforation (OPEN-CLEAN [CABG, CTO Length,

nary artery revascularization downgraded the indi-

EF < 50%, Age, CalciﬁcatioN] score),8 have been

cation for CTO PCI from Class 2a to 2b. While expert

developed to assess the risk of complications.

operators

The

PROGRESS-CTO

complications

score

can

achieve

technical

success

rates

was

exceeding 85%, limiting MACE is essential, consid-

developed 6 years ago to facilitate estimation of the

ering that the main indication for CTO PCI is allevi-

risk of any of the following adverse events prior to

ation of symptoms.18,19 To address this need, we

hospital discharge: death, MI, recurrent symptoms

updated our MACE risk score based on the outcomes

requiring urgent repeat target vessel revasculariza-

of >10,000 CTO PCIs and created separate complica-

tion with PCI or CABG, tamponade requiring either

tion scores allowing estimation of the risk of multiple

pericardiocentesis or surgery, and stroke. 7 The score

complications (MACE, mortality, pericardiocentesis,

was based on a derivation set of 1,065 and a valida-

and acute MI). The updated MACE score had signiﬁ-

tion set of 504 CTO PCIs and included 3 variables (age,

cantly better AUC and net reclassiﬁcation improve-

lesion length, and use of the retrograde approach).

ment. We also provided risk percentage intervals
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(Figures 3A to 3B) corresponding to each score and

pericardiocentesis risk. While use of the retrograde

the proportion of patients falling in each of the risk

approach signiﬁcantly increased the success rate of

scores within the PROGRESS-CTO registry, and pro-

CTO PCI, it is also associated with higher complica-

vided calculators with continuous outcomes (eg, age,

tion rates.25 The retrograde approach should, there-

LVEF) to allow individualized risk calculation.

fore, not be the initial crossing strategy, if feasible.

Older age, moderate-severe calciﬁcation, and the
use of ADR or the retrograde approach were independently associated with higher risk of MACE,
death,

and

pericardiocentesis.

This

ﬁnding

is

consistent with other studies and older age is also
included in the ORA and CASTLE scores.3,13 Older
patients are more likely to have complex coronary
anatomy and high prevalence of comorbidities that
could lead to complications. 20 CTO lesion length was
associated with higher MACE rates in the initial
PRORESS-CTO complications score,7 and is part of
the CL, J-CTO, Ellis, RECHARGE, W-CTO, E-CTO, and
CASTLE-CTO scores; however, the latter scores were
designed to estimate the likelihood of technical
success or failure, whereas our scores were created
to assess the risk of complications. While in the
OPEN-CLEAN perforation score, CTO length was
found to be associated with increased perforation
risk,8 our current analysis did not show any inde-

STUDY LIMITATIONS. First, the PROGRESS-CTO reg-

istry is subject to the limitations of observational
studies. Second, we do not have independent angiographic and clinical event adjudication. Third, biomarkers for MI were not systematically collected after
CTO PCI, which could underestimate the MI rate.
Fourth, the cases from which the models were built
were performed between 2012 and 2022, which could
create heterogeneity. Fifth, not all standard statistical
conventions were followed (10:1 events per variable
ratio), and as such the MI and mortality models may
be overﬁtted. Therefore, there is a need for replication in other patient series. Sixth, operators in
PROGRESS-CTO registry are highly experienced,
potentially limiting extrapolation of the results to all
CTO PCI practices. Seventh, long-term follow-up data
are not available for the entire cohort.

CONCLUSIONS

pendent association between CTO length and risk of
complications. We identiﬁed female sex as an independent risk factor for MACE and pericardiocentesis.

Using 8 variables (age, sex, calciﬁcation status,
stump, LVEF, prior CABG, atrial ﬁbrillation, crossing

This ﬁnding is similar to other studies in which

strategy), we created the PROGRESS-CTO MACE,

women were shown to have higher perforation and

PROGRESS-CTO

bleeding rates.21,22

cardiocentesis, and PROGRESS-CTO acute MI risk

mortality,

PROGRESS-CTO

peri-

Our analysis revealed an independent association

scores that showed acceptable to excellent discrimi-

between moderate-severe lesion calciﬁcation and

nation for event prediction. These tools can be used

worse

pericardiocentesis.

to assess periprocedural complication risk and guide

Lesion calciﬁcation is incorporated in the CL, J-CTO,

patient counseling and procedural planning but need

RECHARGE, W-CTO, and CASTLE scores. Coronary

validation in independent datasets.

MACE,

mortality,

and

calciﬁcation can hinder CTO crossing as well as
equipment delivery and lesion expansion, especially
when combined with tortuosity. 23 Heavily calciﬁed
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